NeoDynamics will be granted another European patent for its pulse biopsy tools
STOCKHOLM – January 14, 2020. NeoDynamics AB (Spotlight Stock Market: NEOD), a MedTech company dedicated to advancing diagnosis and care of breast cancer, today announces that the European Patent Office (EPO) has issued a Communication under Rule 71(3) EPC (Notice of Allowance) and intends to grant a European patent for NeoDynamics pulse biopsy tools, including a multi-purpose driver supporting several different needle options. The decision will be published in the European Patent Bulletin, once the requirements concerning the translation of the claims and payment of all fees are fulfilled by NeoDynamics.
“This is very exciting and supports our launch of the pulse biopsy system NeoNavia, including three needle options for all ultrasound led biopsy procedures. This will reinforce our patent position in Europe. We continue to develop our portfolio of proprietary assets to further expand our business opportunities and to support our product.”, says Anna Eriksrud, CEO NeoDynamics. “The pioneering biopsy system has already gained significant interest, and we have managed to receive the first commercial orders, despite the challenging business environment following the pandemic. Ultrasound guided biopsy in breast and axilla is perceived as critical to ensure an early and adequate diagnosis and ultimately improve patient outcomes".
For additional information please contact:
Anna Eriksrud, CEO NeoDynamics, Phone : +46 +46 (0) 708 444 966, e-mail: email@example.com
The information was submitted for publication, on January 14, 2021 at 08.30 (CET).
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. The system is designed to offer clinicians and patients accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden.
NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.
About the pulse technology
The patented pulse technology is based on a pneumatically driven mechanism that enables high precision and control when inserting and positioning the biopsy needle, independent of tissue type, size and location. The pneumatic driver that generates the pulses is placed in a handheld instrument. With power from the base-unit, the driver accelerates the needle with great control even over a short distance, enabling its distinct stepwise insertion without the risk of destroying surrounding tissue. This facilitates ease of access and flexibility in sampling, even in very small lesions in delicate and difficult locations.